217 related articles for article (PubMed ID: 35545330)
1. Role of metformin in the diagnosis, prevention, and treatment of hepatocellular carcinoma.
Xiong S; Liu W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Mar; 47(3):364-373. PubMed ID: 35545330
[TBL] [Abstract][Full Text] [Related]
2. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.
Chen HP; Shieh JJ; Chang CC; Chen TT; Lin JT; Wu MS; Lin JH; Wu CY
Gut; 2013 Apr; 62(4):606-15. PubMed ID: 22773548
[TBL] [Abstract][Full Text] [Related]
3. Recent Insights of Metformin on Hepatocellular Carcinoma (HCC).
Wang K; Zhang K; Zhang X; Chen D; Jiang S
Mini Rev Med Chem; 2023; 23(11):1154-1166. PubMed ID: 35747976
[TBL] [Abstract][Full Text] [Related]
4. Diabetes mellitus and metformin in hepatocellular carcinoma.
Fujita K; Iwama H; Miyoshi H; Tani J; Oura K; Tadokoro T; Sakamoto T; Nomura T; Morishita A; Yoneyama H; Masaki T
World J Gastroenterol; 2016 Jul; 22(27):6100-13. PubMed ID: 27468203
[TBL] [Abstract][Full Text] [Related]
5. Metformin and risk of hepatocellular carcinoma: are statins the missing link?
Singh S; Singh PP
Gut; 2013 Jun; 62(6):951-2. PubMed ID: 23263525
[No Abstract] [Full Text] [Related]
6. Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway.
Sun R; Zhai R; Ma C; Miao W
Cancer Med; 2020 Feb; 9(3):1141-1151. PubMed ID: 31830378
[TBL] [Abstract][Full Text] [Related]
7. Authors' response: Metformin and risk of hepatocellular carcinoma--a study focused on anti-diabetic agents.
Wu CY; Chen HP
Gut; 2013 Jun; 62(6):952. PubMed ID: 23355550
[No Abstract] [Full Text] [Related]
8. Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection.
Chan KM; Kuo CF; Hsu JT; Chiou MJ; Wang YC; Wu TH; Lee CF; Wu TJ; Chou HS; Lee WC
Liver Int; 2017 Mar; 37(3):434-441. PubMed ID: 27775209
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome.
Cauchy F; Mebarki M; Albuquerque M; Laouirem S; Rautou PE; Soubrane O; Raymond E; Bedossa P; Paradis V
Gut; 2015 Sep; 64(9):1498-500. PubMed ID: 26123027
[No Abstract] [Full Text] [Related]
10. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
[TBL] [Abstract][Full Text] [Related]
11. Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma.
Petrushev B; Tomuleasa C; Soritau O; Aldea M; Pop T; Susman S; Kacso G; Berindan I; Irimie A; Cristea V
Exp Oncol; 2012; 34(1):17-24. PubMed ID: 22453143
[TBL] [Abstract][Full Text] [Related]
12. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review.
Cunha V; Cotrim HP; Rocha R; Carvalho K; Lins-Kusterer L
Ann Hepatol; 2020; 19(3):232-237. PubMed ID: 31836424
[TBL] [Abstract][Full Text] [Related]
13. Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells.
Harati R; Vandamme M; Blanchet B; Bardin C; Praz F; Hamoudi RA; Desbois-Mouthon C
Mol Pharmacol; 2021 Jul; 100(1):32-45. PubMed ID: 33990407
[TBL] [Abstract][Full Text] [Related]
14. Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway.
Xiong Y; Lu QJ; Zhao J; Wu GY
Asian Pac J Cancer Prev; 2012; 13(7):3275-9. PubMed ID: 22994747
[TBL] [Abstract][Full Text] [Related]
15. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
16. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Tseng CH
Liver Int; 2018 Nov; 38(11):2018-2027. PubMed ID: 29956875
[TBL] [Abstract][Full Text] [Related]
17. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis.
Zhang ZJ; Zheng ZJ; Shi R; Su Q; Jiang Q; Kip KE
J Clin Endocrinol Metab; 2012 Jul; 97(7):2347-53. PubMed ID: 22523334
[TBL] [Abstract][Full Text] [Related]
18. Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP.
Tian Y; Tang B; Wang C; Sun D; Zhang R; Luo N; Han Z; Liang R; Gao Z; Wang L
Oncotarget; 2016 Jul; 7(29):46230-46241. PubMed ID: 27323827
[TBL] [Abstract][Full Text] [Related]
19. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells.
Saito T; Chiba T; Yuki K; Zen Y; Oshima M; Koide S; Motoyama T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Tada M; Kanai F; Takiguchi Y; Iwama A; Yokosuka O
PLoS One; 2013; 8(7):e70010. PubMed ID: 23922888
[TBL] [Abstract][Full Text] [Related]
20. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma.
Wang CH; Wey KC; Mo LR; Chang KK; Lin RC; Kuo JJ
Asian Pac J Cancer Prev; 2015; 16(9):3595-604. PubMed ID: 25987009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]